source
- Regeneron posts mid-stage POTS data; Kyverna completes CAR-T filingPlus, news about Merck KGaA, Rezolute, Vir, Orakl and Cellectis. Regeneron’s mid-stage POTS data: The biotech’s monoclonal antibody, baloncibart, given at 450 mg led to an average 11.4-beat-per-min…
- Cerevance appoints Karl Kieburtz as new chief medical officerSTAT+ runs a regular column that tracks personnel moves in the pharmaceutical sector. The piece highlights recent hires, promotions and transfers across companies. Cerevance announced that Karl Ki…